Literature DB >> 14719083

Prostate derived Ets transcription factor shows better tumor-association than other cancer-associated molecules.

Ali Ghadersohi1, Kunle Odunsi, Shashikant Lele, Yvonne Collins, William R Greco, Janet Winston, Ping Liang, Ashwani K Sood.   

Abstract

We previously reported that prostate derived Ets transcription factor (PDEF) is a breast tumor-associated molecule. To obtain further insights into PDEF expression in other human tumor types, a cDNA library database from human adult normal and tumor tissues was compiled and searched for PDEF distribution. The results showed that PDEF is present at relative higher frequencies in the cDNA libraries from brain, breast, lung and ovarian tumors in comparison to those from the corresponding normal tissues. RT/PCR analysis of PDEF expression in ovarian tumors confirmed that PDEF is expressed in 36 out of 51 (71%) ovarian tumors. Further comparison of the distribution of PDEF with other widely recognized cancer-associated molecules showed that PDEF has more restricted distributions than Her-2/neu, Bcl-2, survivin or telomerase in cDNA libraries from normal human tissues and more increased distribution than Her-2/neu, CA-125, Bcl-2, survivin and telomerase in cDNA libraries from brain (except survivin), breast, lung and ovarian tumors. These data together show a better tumor-association for PDEF and suggest that PDEF is a more suitable target for developing specific cancer therapies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14719083

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

1.  [Antiandrogen strategies in prostate cancer: reconstitution of oestrogen receptor beta].

Authors:  P Thelen; A Strauss; M Stettner; S Kaulfuss; R-H Ringert; H Loertzer
Journal:  Urologe A       Date:  2010-09       Impact factor: 0.639

2.  Prostate-derived Ets transcription factor (PDEF) downregulates survivin expression and inhibits breast cancer cell growth in vitro and xenograft tumor formation in vivo.

Authors:  Ali Ghadersohi; Dalin Pan; Zahra Fayazi; David G Hicks; Janet S Winston; Fengzhi Li
Journal:  Breast Cancer Res Treat       Date:  2006-08-08       Impact factor: 4.872

3.  Global gene expression analysis identifies PDEF transcriptional networks regulating cell migration during cancer progression.

Authors:  David P Turner; Victoria J Findlay; A Darby Kirven; Omar Moussa; Dennis K Watson
Journal:  Mol Biol Cell       Date:  2008-06-25       Impact factor: 4.138

4.  Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression.

Authors:  Suhaida A Selamat; Brian S Chung; Luc Girard; Wei Zhang; Ying Zhang; Mihaela Campan; Kimberly D Siegmund; Michael N Koss; Jeffrey A Hagen; Wan L Lam; Stephen Lam; Adi F Gazdar; Ite A Laird-Offringa
Journal:  Genome Res       Date:  2012-05-21       Impact factor: 9.043

5.  Upregulation of SPDEF is associated with poor prognosis in prostate cancer.

Authors:  Jan Meiners; Katharina Schulz; Katharina Möller; Doris Höflmayer; Christoph Burdelski; Claudia Hube-Magg; Ronald Simon; Cosima Göbel; Andrea Hinsch; Viktor Reiswich; Sören Weidemann; Jacob R Izbicki; Guido Sauter; Frank Jacobsen; Christina Möller-Koop; Tim Mandelkow; Niclas C Blessin; Florian Lutz; Florian Viehweger; Maximillian Lennartz; Christoph Fraune; Hans Heinzer; Sarah Minner; Sarah Bonk; Hartwig Huland; Markus Graefen; Thorsten Schlomm; Franziska Büscheck
Journal:  Oncol Lett       Date:  2019-09-19       Impact factor: 2.967

6.  Gene expression of circulating tumour cells in breast cancer patients.

Authors:  E Bölke; K Orth; P A Gerber; G Lammering; R Mota; M Peiper; C Matuschek; W Budach; E Rusnak; S Shaikh; B Dogan; H B Prisack; Hans Bojar
Journal:  Eur J Med Res       Date:  2009-09-28       Impact factor: 2.175

Review 7.  ELF3, ELF5, EHF and SPDEF Transcription Factors in Tissue Homeostasis and Cancer.

Authors:  Ian Y Luk; Camilla M Reehorst; John M Mariadason
Journal:  Molecules       Date:  2018-08-30       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.